CABG or stents?
Compare the whole decision.

There is no single answer for every patient. The comparison depends on coronary anatomy and complexity, left-main or multivessel disease, diabetes, heart function, symptoms, prior procedures, procedural risks, expected durability, medication considerations, and patient priorities. The review explains how the documented factors in your record shape the discussion without assuming one option is always superior.

Important factors may include which vessels are diseased, lesion location and complexity, whether the left main or several vessels are involved, diabetes, left-ventricular function, kidney disease, bleeding or stroke risk, prior stents or surgery, completeness of revascularization, and the outcomes and burdens that matter most to you.

Diabetes and multivessel disease can make the longer-term evidence and the completeness of revascularization especially relevant, but they do not determine the answer by themselves. The useful comparison also considers anatomy, operative and PCI risk, heart function, other health conditions, and personal priorities.

No single webpage or isolated finding can determine treatment. Left-main disease requires careful evaluation of lesion location and complexity, the rest of the coronary anatomy, heart function, procedural risks, and patient circumstances. Depending on the case, CABG, PCI, or further evaluation may deserve discussion with the treating Heart Team.

When the necessary inputs are available, the review considers three surgical-risk approaches—STS PROM, EuroSCORE II, and AATS—separately and makes missing inputs visible. PCI-related considerations may include bleeding, stroke, kidney, vascular, contrast, and antiplatelet-therapy factors documented in the record. No model predicts an individual outcome with certainty.

PCI often involves a shorter initial recovery, while CABG generally requires a larger recovery commitment. Longer-term considerations can include completeness and durability of revascularization, graft or stent performance, the possibility of repeat procedures, and ongoing medication needs. The report puts those trade-offs in the context of your specific record.

Both strategies are usually paired with guideline-directed medical therapy. After PCI, dual antiplatelet therapy may be particularly important for a defined period, which can affect bleeding risk, adherence, and timing of other procedures. The review organizes the medications, contraindications, and practical considerations documented in your case for discussion with your treating clinicians.

A cardiac surgeon and cardiologist independently review the same complete record, then confer and co-sign one patient-facing WHITEGLOVE Insights™ report. Their two clinical perspectives are included at every service level.

The co-signed written WHITEGLOVE Insights™ review starts at $495. A live physician consultation is optional, available in higher-tier services, and costs extra. WHITEGLOVEMD is a direct-pay service and does not submit insurance claims.

The 24-hour turnaround begins after the records required for the review have been received and confirmed complete. Time spent requesting or collecting records is outside that window. The records team can help identify and gather what is needed with your authorization.

No referral or travel is required. The medical-record review is completed remotely. You may choose the written review alone or add an optional live physician consultation through a higher-tier service.

No. WHITEGLOVEMD provides independent educational decision support and medical-record review. It does not diagnose, order, prescribe, provide emergency care, establish a treating relationship, or replace the clinicians responsible for your care.